Company name
Nanolynx Biologics AG
Company profile
Nanolynx is developing first-in-class conditionally active nanobody-drug conjugates (CA-NDCs) for hard-to-treat solid tumors. Our IntelliBody™ platform combines ML-driven nanobody engineering with pH-gated tumor-selective activation, addressing the two fundamental failures of conventional antibody-drug conjugates (ADCs): poor tissue penetration and dose-limiting toxicity.
Date, time and room information
Tuesday, May , 15:15 - 15:30, room Singapore
Category
Emerging biotech company
Title of the presentation
Reimagining Solid Tumor Therapy with Conditionally Active Nanobody-Drug Conjugates
Speaker information
| Name | Position | Institution |
|---|---|---|
| Georg Rüedi | Co-Founder & CEO |
